{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041326","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.276712+00:00","generated_at":"2026-06-11T18:41:18.949114+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ORIC Q2 2023 cash $273.7M, $85M private placement; clinical data milestones set","bullets":["Cash and investments $273.7M as of June 30, 2023; expected to fund operating plan into late 2025.","Completed $85M private placement with Nextech, EcoR1, Frazier, Venrock, Boxer investors.","Initial Phase 1b data for ORIC-114 at ESMO Oct 20-24, 2023; ORIC-533 data Q4 2023; ORIC-944 data Q1 2024.","R&D expenses $18.8M in Q2 2023 vs $13.8M in Q2 2022, increase due to program advancement and personnel."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041326","json":"https://secwatch.observer/filing/0000950170-23-041326.json","markdown":"https://secwatch.observer/filing/0000950170-23-041326.md","text":"https://secwatch.observer/filing/0000950170-23-041326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023041326/0000950170-23-041326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023041326/oric-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:41:18.949114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f982504d2f4e8c898bb7450a76e20e4c4f4cfc2","claim":"Oric Pharmaceuticals, Inc. reported financial results for the fiscal quarter ended June 30, 2023.","evidence_excerpt":"ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023041326/0000950170-23-041326-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}